Oral News and Research

RSS

Early stage pancreatic cancer expresses antigen targeted by Immunomedics' PAM4 antibody

Immunomedics has reported in an oral presentation at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) that the antigen targeted by the humanized PAM4 antibody is expressed in early stage pancreatic cancer specimens, a stage before the tumor becomes invasive.

18 Apr 2007

Avalon Pharmaceuticals announces results of AVN944 biomarker study

Avalon Pharmaceuticals has announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx technology to identify gene signatures that may be useful for patient stratification.

18 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007

Statement by ADA on court's ruling on dental amalgam fillings

The American Dental Association (ADA) welcomes Friday's ruling by the U.S. Court of Appeals for the District of Columbia stating that the court cannot force the Food and Drug Administration to tighten restrictions on the use of dental amalgam fillings.

17 Apr 2007

Innovative treatment option for excessive sweating

An estimated 3 percent of the world population, or about 197 million people suffer from some form of hyperhidrosis (excessive sweating), many of whom do not receive proper diagnosis or treatment.

17 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

Potential treatments for mouth ulcers

The drug pentoxifylline appears to have limited benefit in the first-line treatment of mouth ulcers due to recurrent apthous stomatitis, according to a report in the April issue of Archives of Dermatology.

17 Apr 2007

Biomira selects PX-866 as clinical development candidate

Biomira Inc. has announced that it has selected PX-866 as its next clinical development candidate.

17 Apr 2007

New diagnostic technologies to predict and monitor cancer risks

Molecular messages and signals circulating in blood or contained in cells lining the airway can identify early stage cancer, according to research reported at the 2007 Annual Meeting of the American Association for Cancer Research.

16 Apr 2007

Human Genome Sciences reports results of phase 2b trial of Albuferon

Human Genome Sciences has reported results at Week 12 following the completion of therapy (SVR12) in a Phase 2b clinical trial of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are naive to interferon alpha-based treatment regimens.

16 Apr 2007

Essential medicines for children

Following recommendations from the Expert Committee on Essential Medicines, the World Health Organization (WHO) will immediately begin work to create a medicines list specifically tailored to children's needs. A group of experts will meet in July 2007 to produce the first international list of medicines to tackle diseases with high mortality and morbidity rates in children.

16 Apr 2007

CDC warns about threat of drug resistant gonorrhoea

According to the U.S. Centre for Disease Control and Prevention (CDC), gonorrhoea affects as many as 700,000 Americans each year and the sexually transmitted disease has now become so drug resistant doctors are running out of options with which to treat it.

16 Apr 2007

Lupin Pharmaceuticals receives FDA approval for Suprax

Lupin Pharmaceuticals has announced that the U.S. Food and Drug Administration (US FDA) has approved the company's application for Suprax (Cefixime for oral suspension 200mg/5ml).

15 Apr 2007

Cytokinetics initiates of phase II clinical trial for CK-1827452

Cytokinetics has announced the initiation of a Phase II clinical trials program evaluating CK-1827452, a novel cardiac myosin activator for the potential treatment of patients with either acutely decompensated or chronic heart failure.

15 Apr 2007

CuraGen announces results with Belinostat and Velafermin

CuraGen Corporation has announced that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007.

15 Apr 2007

Curcumin has anticancer effects

Curry powder is a mixture predominantly composed of turmeric root extract and other spices such as coriander and fenugreek.

14 Apr 2007

New oral fluid-based HIV test shows great promise

A convenient, easy to use, and rapid alternative to blood-based HIV testing may become the new standard for field testing according to a new MUHC study.

12 Apr 2007

New vaccine to prevent type-1 polio three times as effective as standard vaccine

The study found that each dose of the new monovalent oral poliovirus vaccine, known as mOPV1, protected 30% of susceptible children in northern India against paralytic poliomyelitis. The standard trivalent vaccine in the same setting protected just 11% of children per dose.

12 Apr 2007

Schering-Plough commits to chronic hepatitis C research

Schering-Plough has reaffirmed its commitment to advancing the science and treatment of chronic hepatitis C virus (HCV) infection with several key data presentations at the European Association for the Study of the Liver (EASL) 42nd annual meeting in Barcelona, Spain, April 11-15.

11 Apr 2007

Barr Pharmaceuticals receives Notice of Allowance for Seasonale patent

Barr Pharmaceuticals has announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the reissuance of U.S. Patent 5,895,032 ('032), relating to Barr's SEASONALE extended-cycle oral contraceptive.

10 Apr 2007